• FirefoxInstall the new Firefox »
  •  Dow Up1.49% Nasdaq Up1.15%

    Raptor Pharmaceuticals Corp. (RPTP)

    -NasdaqGM
    12.04 Up 0.07(0.58%) Mar 30, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Raptor Pharmaceuticals Corp.
    7 Hamilton Landing
    Suite 100
    Novato, CA 94949
    United States - Map
    Phone: 415-408-6200
    Fax: 415-382-8002
    Website: http://www.raptorpharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:123

    Business Summary 

    Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults, as well as in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. Its clinical development programs include RP103 that is used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidates comprise Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical product candidates include cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Raptor Pharmaceuticals Corp.

    Corporate Governance 
    Raptor Pharmaceuticals Corp.’s ISS Governance QuickScore as of Mar 1, 2015 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 5; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Ms. Julie Anne Smith , 44
    Chief Exec. Officer, Pres and Director
    627.00K0.00
    Mr. Thomas E. Daley , 52
    Chief Bus. Officer
    401.00K0.00
    Mr. David A. Happel , 53
    Chief Commercial Officer
    174.00K0.00
    Mr. Frank Lanza ,
    Corp. Controller
    275.00K0.00
    Dr. Todd C. Zankel Ph.D., 51
    Co-Founder and Chief Scientific Officer
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders